Genomed S.A.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2010-12-30
Share capital
132,130.10 PLN
Activity description

Genomed is a company that provides genetic diagnostics based on DNA sequencing and offers services for scientific research. It specializes in the analysis of any gene and also provides oligonucleotide synthesis. Additionally, Genomed is involved in personalized medicine and genome analysis.

Registered address
Ponczowa 12, 02-971 Warszawa, Poland
Website
Phone
Social media
Electronic delivery address
AE:PL-75101-20426-SHSIA-21

Financials

Revenue history (in k)

From the notes

Current income tax (CIT due)$150,233

Filing timeliness

Financial statements were filed on time, on average 26 days early. All were audited by a statutory auditor.

  • 202509/07/2026
  • 202402/07/2025
  • 202302/07/2024
  • 202207/07/2023
  • 202104/07/2022
  • 202002/07/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Stock quotes

PLN 32.80
-0.40 (-1.20%)
32.8033.0033.2033.4033.6032.8010:0012:0014:0016:00
Open
PLN 33.60
High
PLN 33.60
Low
PLN 32.80
Volume
26
Avg. vol.
59.4
Market cap
PLN 43.34M
P/E ratio
20.76
EPS
PLN 1.58
Shares outstanding
1.32M
52-week
PLN 32.80 – 39.40
Dividend yield
4.57%
Dividend
PLN 1.50
Ex dividend date
Jul 6, 2026
Exchange
NewConnect

Quarterly results

PeriodRevenueEBITNet profit
Q3 2026USD 2.05mUSD 132.09kUSD 78.88k
Q2 2026USD 1.93mUSD 165.32kUSD 123.99k
Q1 2026USD 1.83mUSD -4.05kUSD -13.24k
Q4 2025USD 2.20mUSD 512.81kUSD 408.84k

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 7.1%
Top 3.2%
City · Warszawa4,705 / 56,729
Top 8.3%
Voivodeship · Mazowieckie6,660 / 76,892
Top 8.7%
Country · Poland24,590 / 297,069
Top 8.3%

Results vs industry

Revenue
This companyUSD 7.37mMedianUSD 153.26kAverageUSD 4.77m
Net profit
This companyUSD 853.73kMedianUSD -293.45AverageUSD 306.55k
Operating costs
This companyUSD 6.24mMedianUSD 188.47kAverageUSD 4.59m
Assets
This companyUSD 4.15mMedianUSD 281.58kAverageUSD 8.35m

Websites

The sites are available in: Polish, English and Ukrainian. The sites target these markets: United Kingdom and Ukraine.

  • Google Tag ManagerCloudflare
  • parento.plParento
    Google Tag Manager
  • sancotest.plTest Sanco – nieinwazyjny prenatalny test genetyczny. Badania prenatalne
    JoomlaGoogle Tag Manager

Public procurement

82 tenders recorded as contractor: 61 national ($1,362,061) and 21 EU ($1,888,097).

SubjectAmount
Sekwencjonowanie genomowe wraz z przygotowaniem bibliotek oraz analizą bioinformatyczną - próbki w postaci materiału genetycznego (dna bakterii)
–
Supply of reagents and small laboratory equipment for the Cancer Genetic and Molecular Diagnostics Laboratory
–
Supply of reagents, consumables and other items covered by the contract.
$9,206

National Health Fund (NFZ) contracts

The company has been an NFZ healthcare provider since 2011. In 2012 it is performing 1 contract worth USD 2.16k. All its contracts were worth USD 12.99k in total.

NFZ contract value by year (in k USD)

Type of careNFZ branchContractsValue in 2012
Outpatient specialist caremazowieckie1USD 2.16k

Trademarks

The company holds 8 active trademarks registered with the Polish Patent Office. The first mark was filed in 2009.

MarkNumberClassesStatusProtected until
Parento Z.53633335, 42, 44Protected Nov 10, 2031
genome23 Z.5128299, 35, 44Protected Apr 23, 2030
infano Z.51163935, 42, 44Protected Mar 18, 2030
MIMO Z.5115969, 35, 42, 44Protected Mar 18, 2030
brovar VARIANT BROWSER Z.5116459, 35Protected Mar 18, 2030
MarkProtected until
Parento Nov 10, 2031
genome23 Apr 23, 2030
infano Mar 18, 2030
MIMO Mar 18, 2030
brovar VARIANT BROWSER Mar 18, 2030

Authorized Representatives

Andrzej Henryk Pałucha age 67 – Management Board Member
Anna Maria Boguszewska-Chachulska age 61 – President of the Management Board
Anna Maria Piotrowska-Mietelska age 44 – Management Board Member
Łukasz Brejnakowski age 42 – Management Board Member
Iwona Wach age 51 – Management Board Member

Manner of representation

The company may be represented by two members of the management board acting jointly or by a member of the management board acting with a commercial proxy.

Supervisory board

Mieczysław Andrzej Prószyński age 73 – Supervisory Board Member
Tomasz Bykowski age 53 – Supervisory Board Member
Grzegorz Piotr Gromada age 56 – Supervisory Board Member
Jakub Józef Swadźba age 60 – Supervisory Board Member
Piotr Mariusz Skowron age 64 – Supervisory Board Member

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2007-09-12.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Buildings and premises
PLN 20,226

MSiG notices

Publication dateEvent
Feb 9, 2017Bankruptcy notice
Oct 5, 2012Commercial Companies Code notice

Public aid

10 public aid cases recorded, with a total value of $857,098.

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$204.6K
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
$2,116
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
$1,566

European Funds

ProjectEU co-financing
Development of methods for non-invasive genetic diagnosis and prevention of cancer – liquid biopsy.
$525.3K

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Gyncentrum sp. z o.o.
Medgen Kamila Czerska I Wspólnicy sp. k.
Histamed Dc sp. z o.o.
Alab sp. z o.o.
Akademicki Ośrodek Diagnostyki Patomorfologicznej I Genetyczno-Molekularnej sp. z o.o.
Testdna sp. z o.o.
Genos sp. z o.o.
Warsaw Genomics S.A.
Read-Gene S.A.
Inngen Laboratorium Badań Genetycznych sp. z o.o.

Change history

DateEvent
2015-04-24PKD change
2011-04-12Share capital increase
2010-12-30Entered in the register

FAQ

Last updated: 2026-10-04